ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 161 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2018. The put-call ratio across all filers is 0.99 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $376,630 | -75.3% | 236,874 | -3.3% | 0.00% | – |
| Q4 2022 | $1,526,812 | -16.9% | 245,074 | -10.7% | 0.00% | – |
| Q3 2022 | $1,838,000 | -1.3% | 274,425 | -6.3% | 0.00% | – |
| Q2 2022 | $1,862,000 | +37.1% | 292,778 | 0.0% | 0.00% | – |
| Q1 2022 | $1,358,000 | +24.4% | 292,778 | +34.1% | 0.00% | – |
| Q4 2021 | $1,092,000 | +70.1% | 218,320 | +1926.5% | 0.00% | – |
| Q4 2019 | $642,000 | -9.8% | 10,773 | -29.6% | 0.00% | – |
| Q2 2019 | $712,000 | +16.0% | 15,296 | 0.0% | 0.00% | – |
| Q1 2019 | $614,000 | -25.8% | 15,296 | -14.9% | 0.00% | – |
| Q4 2018 | $827,000 | +63.1% | 17,979 | +39.0% | 0.00% | – |
| Q2 2018 | $507,000 | -90.8% | 12,935 | -83.0% | 0.00% | -100.0% |
| Q1 2018 | $5,488,000 | +198.1% | 75,869 | +171.3% | 0.00% | – |
| Q4 2017 | $1,841,000 | +17.9% | 27,961 | -10.3% | 0.00% | – |
| Q3 2017 | $1,562,000 | +302.6% | 31,159 | +272.0% | 0.00% | – |
| Q2 2017 | $388,000 | +53.4% | 8,376 | +206.8% | 0.00% | – |
| Q1 2015 | $253,000 | – | 2,730 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,629,835 | $116,685,000 | 25.08% |
| Aviva Holdings Ltd. | 1,200,100 | $53,248,000 | 14.21% |
| Boxer Capital, LLC | 1,375,000 | $61,009,000 | 6.77% |
| BB BIOTECH AG | 3,282,964 | $145,665,000 | 3.86% |
| Rhenman & Partners Asset Management AB | 353,961 | $15,705,000 | 1.57% |
| PFM Health Sciences, LP | 1,970,134 | $87,415,000 | 1.28% |
| Bellevue Group AG | 391,852 | $17,386,000 | 1.10% |
| Pentwater Capital Management LP | 2,351,500 | $104,336,000 | 0.88% |
| Partner Investment Management, L.P. | 25,440 | $1,129,000 | 0.86% |
| SABBY MANAGEMENT, LLC | 100,369 | $4,453,000 | 0.57% |